Clinical and laboratory phenotype of patients experiencing statin intolerance attributable to myalgia
| Autor: | Leonard J. Harris, Murray Heimberg, Sabitha Pabbathi, Rashmi Thapa, Marshall B. Elam, Ron Braden, Michael D. Brown, Richard D. Childress |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
myalgia
Male medicine.medical_specialty Statin medicine.drug_class Endocrinology Diabetes and Metabolism Population Pain Hyperlipidemias Disease Muscular Diseases Internal medicine Internal Medicine Medicine Humans cardiovascular diseases Adverse effect education Creatine Kinase Myositis Aged education.field_of_study Nutrition and Dietetics business.industry nutritional and metabolic diseases Type 2 Diabetes Mellitus Middle Aged medicine.disease Phenotype Case-Control Studies Cohort Physical therapy lipids (amino acids peptides and proteins) Female medicine.symptom Hydroxymethylglutaryl-CoA Reductase Inhibitors Cardiology and Cardiovascular Medicine business Follow-Up Studies |
| Zdroj: | Journal of clinical lipidology. 5(4) |
| ISSN: | 1933-2874 |
| Popis: | Background Muscle pain without elevation of serum creatine phosphokinase (CPK) (myalgia) is the most common medication-related adverse effect of statin therapy; it occurs in up to 10% of patients who are prescribed statin therapy. Although much is known regarding risk factors for overt myositis, very few studies have provided information on this common form of statin intolerance. Methods We defined a detailed clinical and laboratory phenotype of a cohort of patients referred to the lipid clinic of a governmental health maintenance organization for statin intolerance attributable to muscle pain without CPK elevation (myalgia) and characterized their response to alternative lipid-lowering therapy. Baseline and follow-up data were analyzed for 104 patients with statin intolerance attributable to myalgia and 211 statin-tolerant control patients identified from the referral population. Results Among patients with myalgia, more were white and had hypertension. The prevalence of known risk factors for overt myositis, including renal disease, type 2 diabetes mellitus, thyroid disease, and electrolyte abnormalities, did not differ between statin intolerant and statin tolerant patients. Although individual cases were identified in which the addition of interacting medications was temporally associated with development of statin intolerance, overall use of interacting medications was not more frequent among statin-intolerant patients. The majority of patients were intolerant of two or more statins; however, in more than one-half the cases, successful rechallenge with an alternative statin was accomplished. Despite this and extensive use of nonstatin lipid medications after lipid clinic referral, control of plasma lipoproteins remained significantly worse in statin-intolerant patients. Conclusions Statin intolerance attributable to myalgia is a significant barrier to effective treatment of hyperlipidemia. Conventional clinical risk factors for myositis do not appear to predictive of statin-associated myalgia. These findings underscore the need to better define the pathophysiology of statin-induced myalgia and develop methodologies to guide treatment of statin-intolerant patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect